CompletedPhase 1NCT03008161

Multiple Dose Safety Study of NPT088 in Patients With Mild to Moderate Probable Alzheimer's Disease

Studying Early-onset autosomal dominant Alzheimer disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Proclara Biosciences, Inc.
Principal Investigator
Proclara Biosciences
Proclara
Intervention
NPT088(drug)
Enrollment
83 target
Eligibility
50-85 years · All sexes
Timeline
20162019

Study locations (23)

Collaborators

Alzheimer's Association

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03008161 on ClinicalTrials.gov

Other trials for Early-onset autosomal dominant Alzheimer disease

Additional recruiting or active studies for the same condition.

See all trials for Early-onset autosomal dominant Alzheimer disease

← Back to all trials